Related Experiment Video

Updated: Aug 10, 2025

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

13.7K

The emerging landscape of neo/adjuvant immunotherapy in renal cell carcinoma

Pooya Dibajnia1, Luisa M Cardenas1, Aly-Khan A Lalani1

  • 1Department of Oncology, Juravinski Cancer Centre, McMaster University, Hamilton, ON , Canada.

Human Vaccines & Immunotherapeutics
|February 12, 2023
PubMed

Insights

Adjuvant and neoadjuvant therapies for renal cell carcinoma (RCC) are under investigation. While some immune checkpoint inhibitors show promise, more data is needed to confirm survival benefits in early-stage disease.

Area of Science:

  • Oncology
  • Nephrology
  • Immunotherapy

Background:

  • Adjuvant and neoadjuvant therapies for renal cell carcinoma (RCC) are critical for reducing recurrence risk, representing an unmet clinical need.
  • Recent advancements in metastatic RCC have involved PD-1/PD-L1 immune checkpoint inhibitors (ICIs).
  • Investigating ICIs in early-stage RCC (adjuvant and neoadjuvant settings) aims to determine their clinical benefit in disease trajectory.

Approach:

  • Reviewing current adjuvant/neoadjuvant therapies for RCC.
  • Analyzing the efficacy of immune checkpoint inhibitors (ICIs) in early-stage RCC.
  • Highlighting ongoing research and future opportunities, including combinations of ICIs with targeted therapies and vaccines.

Key Points:

  • Pembrolizumab has demonstrated a disease-free survival benefit in the adjuvant setting for RCC.
  • Results from other ICI studies in the adjuvant/neoadjuvant settings have not yet shown significant benefits.
  • Mature survival data is required to establish the overall survival benefit of ICIs in the curative-intent setting for RCC.

Conclusions:

  • Immune checkpoint inhibitors (ICIs) represent a promising avenue for adjuvant and neoadjuvant therapy in renal cell carcinoma (RCC).
  • Further research and mature data are essential to confirm the long-term efficacy and survival benefits of ICIs in early-stage RCC.
  • Combination strategies involving ICIs with other therapeutic agents are emerging and warrant further investigation.
Keywords:
Immunotherapyadjuvant therapyneoadjuvant therapyrenal cell carcinomavaccine

More Related Videos

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

33.7K
Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

16.8K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
615
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Renal Drug Clearance: Overview01:06

Renal Drug Clearance: Overview

Renal clearance is a crucial parameter in pharmacokinetics that quantifies the rate at which the kidneys excrete a drug. It represents a constant fraction of the central volume of distribution containing the drug that the kidney eliminates per unit of time.
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...
269
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
49